Neural circuits in the hippocampus defy current views about its structure and function.
Brain extracts from AD patients, but not their cerebrospinal fluid, contain exceedingly potent Aβ seeds that survive formaldehyde treatment. The findings further implicate Aβ in prion-like pathology.
More than half of dementia patients near the end of life receive medications that may not help them, according to an analysis of U.S. nursing home data.
Scientists report a case of identical twins with the C9ORF72 DNA expansion—only one has ALS.
Controlling diabetes and hypertension and stopping smoking can slash dementia risk.
Overzealous neural responses may protect some amyloid-bearers from slipping into cognitive decline, a study suggests.
Prescribed to treat anxiety and insomnia, benzodiazepines may do more than put the mind at ease. A new study links their prolonged use to increased Alzheimer’s risk.
Expansions in ataxin 2 predispose people to the ALS end of the ALS-FTD spectrum, and never cause pure FTD, according to a new French study.
When strict quality control standards are followed, low Aβ in cerebrospinal fluid accurately predicts amyloid plaques in people with cognitive impairment in clinical practice.
A new drug combination is better than standard therapy for congestive heart failure. It includes an inhibitor of neprilysin, a protease that digests Aβ in the brain.
Researchers in the United States, France, and Austria honored for pioneering work on deep-brain stimulation and L-dopa.
CRISPR Gene Editing—Poised to Revolutionize Neuroscience? Neuroscientists Probe CRISPR Transgenics and Treatment Paradigms ...
Moving beyond cell culture, neuroscientists are using CRISPR to tweak genes in living animals and perhaps, one day, as therapy in humans.
A hot new tool, CRISPR empowers researchers to slice, dice, and add their own spice to any gene. Neuroscientists are starting to reap the benefits.
The ALS Ice Bucket Challenge has yielded more than $100 million—what research projects should get a share of the action?